Tesamorelin 10mg Vial

Tesamorelin, coded TH9507 during development, is a man-made version of growth hormone-releasing hormone (GHRH). Its backbone is the full 44-residue sequence of human GHRH. The one change is a trans-3-hexenoyl group attached to the N-terminal tyrosine. Native GHRH is cut quickly in plasma, mainly by the enzyme DPP-IV working at that N-terminal end, and the added group is there to slow that breakdown.

The compound is best known as the active ingredient of Egrifta, a US prescription medicine made by Theratechnologies. The FDA approved it for one narrow purpose: reducing excess abdominal fat in HIV-infected adults with lipodystrophy. The label states that it is not indicated for weight-loss management. That approval belongs to Egrifta alone. The material in this vial is a research reagent, not Egrifta, and it is not an approved medicine anywhere.

Remy Research lists tesamorelin as a sealed 10mg lyophilised vial under the ProPeptide label, intended for receptor, assay and analytical work in a laboratory setting. For research use only. Not for human or veterinary use. The full evidence review sits in our tesamorelin research article.

A clearly labelled research format

Each unit is a crimp-sealed glass vial holding 10mg of freeze-dried tesamorelin, packed in cold-chain insulated packaging. It carries the ProPeptide label and is listed by Remy Research as research material only.

A stated purity standard, with honest documentation

The ProPeptide tesamorelin line is supplied to a ≥99% HPLC line standard. No batch-specific Janoshik report has been published for this product yet, and we do not imply otherwise. Our published batch reports currently cover the Retatrutide range and can be checked in the lab results library.

Cold-chain delivery across the UAE

Orders travel by cold-chain courier to all seven emirates, packed to hold 2–8°C. Dubai orders placed before 4 PM qualify for same-day delivery. Elsewhere, orders before 12 PM (noon) arrive the next day. Full terms are on the delivery page.

No outcome promises

We make no fat-loss, body-composition or wellbeing claims for this vial. The clinical results summarised below come from trials of the approved medicine in a defined patient group and do not transfer to research material.

GHRH is the hypothalamic signal that tells the anterior pituitary to release growth hormone. Tesamorelin works at that upstream step rather than being growth hormone itself.

Binding the GHRH receptor

In vitro, tesamorelin binds and activates the human GHRH receptor with a potency similar to the native hormone, according to the Egrifta label. The receptor sits on somatotroph cells in the pituitary.

A stabilised, short-lived molecule

The hexenoyl group improves resistance to enzymatic cleavage, yet the label still reports a mean elimination half-life of roughly 8 minutes in healthy subjects. Its effects are therefore studied through downstream markers rather than circulating drug levels.

Downstream markers: GH and IGF-1

Pituitary release of growth hormone raises IGF-1, and IGF-1 is the marker most trials tracked. In the approved medicine's labelled population, IGF-1 above the normal range was common at 26 weeks, which the label lists as a safety point to monitor.

Several peptides act on the growth hormone axis, but they differ in structure, receptor and stability. The table summarises the structural points from our GHRH peptides comparison. Head-to-head trials between these compounds are largely missing, so the comparison is about chemistry and published readouts, not ranking.

Tesamorelin stands apart mainly because it has randomised human trial data and an approved-product label behind it, though that record is concentrated in one population. A pre-filled Tesamorelin 20mg pen is listed separately with its own documentation.